Incretins are gut-derived circulating peptide hormones that potentiate glucose-dependent insulin secretion following ingestion of a meal. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the major incretin hormones. The insulinotropic actions of endogenously secreted GLP-1 and GIP are transient because both peptides are rapidly cleared by the kidney and inactivated by cleavage at the N-terminus by dipeptidyl peptidase-4 (DPP-4), a ubiquitous exopeptidase. Potentiation of incretin action underlines two therapeutic classes of glucose-lowering agents: GLP-1 receptor (GLP-1R) agonists and DPP-4 inhibitors ([@B1]). Original concepts of GIP and GLP-1 biology, which focused primarily on islet β-cells, have been expanded to include actions on other cell types within and outside the pancreas ([@B2],[@B3]). There is now considerable interest in understanding how the potentiation of incretin action controls multiple facets of pancreatic biology, encompassing the regulation of glucose sensing, hormone secretion, and cell proliferation, differentiation, and survival. Recent studies have suggested that incretin therapies promote pancreatic inflammation as well as aberrant cell proliferation within the endocrine and exocrine pancreas ([@B4],[@B5]); substantial technical and methodological issues, however, limit the generalizability of these findings. This *Perspectives in Diabetes* evaluates the science supporting existing dogma and discusses new concepts, controversies, and uncertainties in the biology of incretin action in the pancreas.

LOCALIZATION OF INCRETIN RECEPTOR EXPRESSION IN THE PANCREAS {#s1}
============================================================

Several dozen commercial antisera are available for detection of GLP-1R and GIP receptor expression by immunohistochemical techniques and Western blotting, and real-time PCR is widely used to quantify expression of incretin receptor genes in pancreatic exocrine and endocrine compartments. Most antisera used to detect GLP-1R expression (by immunohistochemistry or Western blot analysis) are neither sensitive nor specific ([@B6],[@B7]). Important control experiments (absorption of the antibody with a peptide epitope, demonstration that the antibody recognizes only a single protein, and failure to generate a signal in cells that do not express a full-length receptor mRNA transcript or in tissues from *Glp1r*^−/−^ mice) are usually absent. Furthermore, multiple studies describe GLP-1R protein expression in cells or tissues that do not express full-length *Glp1r* mRNA. The widespread use of tightly cropped bands in Western blot analysis precludes accurate assessment of whether a putative band/protein detected by Western blotting is the correct size, the only GLP-1R immunoreactive protein visualized, or one of several unrelated immunoreactive proteins detected by the same antisera.

Scientists who are interested in the expression of incretin hormone receptors face the challenging task of assessing how much, if any, of the data published with these antisera is correct. For example, immunoreactive GLP-1R protein expression or *Glp1r* mRNA transcripts have been detected throughout the heart and ventricle; however, we and others determined that cardiac *Glp1r* expression was restricted to the atria and absent from the ventricles in mice ([@B8]) and rats ([@B9]). How do the limitations of available reagents affect our understanding of incretin action in the pancreas? The putative localization of incretin receptor expression in the exocrine pancreas provides an instructive example. Abundant immunohistochemical GLP-1R expression in ductal and acinar cells was reported in rodent and human pancreas, papillary thyroid cancer, and pancreatic adenocarcinoma ([@B10],[@B11]). Characterization of multiple GLP-1R antisera, including Abcam39072 ([@B11]), one of the reagents used in these studies, revealed major problems with sensitivity and specificity. These antisera detected multiple spurious bands in Western blot analyses of fibroblasts that do not express the GLP-1R and in cellular extracts from *Glp1r*^−/−^ mice ([@B6]). We now extend these analyses to detection of the human GLP-1R. Western blot analysis using fibroblasts transfected with human GLP-1R cDNA shows that Abcam39072 does not detect the human GLP-1R ([Fig. 1](#F1){ref-type="fig"}). A second antiserum, distributed by Novus Biologicals (1940002), recognizes the human GLP-1R protein ([Fig. 1](#F1){ref-type="fig"}) but also detects multiple spurious bands/proteins in control cells that do not express the *Glp1r* ([Fig. 1](#F1){ref-type="fig"}). Similar problems with the sensitivity and specificity of GLP-1R antisera have been described by others ([@B7]). Hence the majority of published studies using multiple GLP-1R antisera must be discounted until the experimental data are independently verified with validated, highly sensitive, and highly specific antisera.

![Characterization of the sensitivity and specificity of antisera against the human GLP-1R. Baby hamster kidney cells were transiently transfected with the vector pcDNA3.1 alone (*lane 1*) or with a human *Glp1r* cDNA tagged at the C-terminus with green fluorescent protein (GFP) cloned into pcDNA3.1 (*lane 2*). Whole-cell extracts were prepared 48 h after transfection and analyzed by immunoblotting with the indicated commercial GLP-1R antibodies or with a rabbit polyclonal antibody against GFP (Abcam ab6556). Molecular mass standards are indicated on the *right*. Both the anti-GLP-1R antibody Novus1940002 and the anti-GFP antibody detected similar immunoreactive proteins of ∼68 and ∼87 kDa, likely representing species of the GLP-1R-GFP fusion protein that were glycosylated differently.](3316fig1){#F1}

Similar concerns relate to the interpretation of some experiments using regular PCR or real-time PCR to detect expression of the incretin receptor gene. Real-time PCR detects *Glp1r* mRNA transcripts by generating an amplicon of less than 100 base pairs, whereas regular PCR frequently uses primer pairs that generate *Glp1r* PCR products that are several hundred base pairs in length; both are far smaller than the entire full-length GLP-1R open reading frame. However, cells may generate noncoding mRNA transcripts detectable by regular or real-time PCR. Analysis of *Gipr* expression revealed ∼64 possible *Gipr* mRNA splice variants in RNA from human adipose tissue, only two of which were predicted to contain an open reading frame sufficient to give rise to a fully functional, membrane-spanning GIP receptor protein ([@B12]). Whether one or more of these variant *Gipr* RNA transcripts encodes a truncated GIP receptor protein that might exhibit dominant negative signaling activity, as described in mouse β-cells ([@B13]), requires further investigation. Furthermore, using a polyclonal antiserum, an immunoreactive GIP receptor protein was detected in human skeletal muscle ([@B12]), a tissue not previously reported to express full-length *Gipr* mRNA transcripts ([@B14]). Despite reports describing the detection of *1*) partial *Glp1r* mRNA transcripts by PCR or *2*) immunoreactive GLP-1R proteins by Western blotting or immunohistochemistry in murine liver, macrophages, or ventricular cardiomyocytes ([@B2]), we could not detect full-length *Glp1r* mRNA transcripts in the same cells and tissues ([@B6],[@B8]).

Given the considerable limitations of commonly used reagents and techniques, how should we interpret available data reporting localization of GLP-1R expression in the endocrine and exocrine pancreas? The difficulty in isolating pure ductal, acinar, or islet cell RNA that is free from contamination by other cell types renders use of such cell fractions suboptimal for the analysis of cell-specific gene expression. Some groups have localized GLP-1R expression in islet α-cells ([@B15]); however, analysis of *Glp1r* mRNA transcripts in RNA from purified murine α-cells and β-cells that were sorted using a fluorescence-activated cell sorter failed to detect *Glp1r* mRNA transcripts in α-cells (K. Furuyama, P. Herrera, personal communication). Similarly, *Glp1r* and *Gcgr* mRNA transcripts were not detected by in situ hybridization in rat or mouse α-cells, respectively ([@B16],[@B17]). Although *Gipr* mRNA transcripts were detected in rodent α-cells ([@B18]), less information is available regarding *Glp1r* or *Gipr* expression in human α-cells. GLP-1R activation stimulates secretion of islet somatostatin, but whether some, most, or few somatostatin-producing δ-cells express the GLP-1R has not been established. DPP-4 expression at the cell surface has been identified on murine α-cells and β-cells and even more strongly on ductal cells ([@B19]); however, whether DPP-4 activity locally regulates bioactive incretin activity within these pancreatic cell types has not been determined.

*Glp1r* mRNA transcripts have been detected in pancreatic ductal human pancreatic adenocarcinoma cell lines ([@B20]). However the GLP-1R agonist exendin-4 failed to stimulate growth or enhance cell survival in five different human pancreatic cancer cell lines that express an endogenous *Glp1r* mRNA transcript. Whether *Glp1r* mRNA transcripts are expressed in non-immortalized pancreatic ductal or acinar cells remains uncertain. Tornehave et al. ([@B16]) were unable to demonstrate *Glp1r* mRNA transcripts in pancreatic duct cells from mice and rats by in situ hybridization, despite detection of an immunoreactive protein in ducts using a GLP-1R antibody that was subsequently shown to exhibit suboptimal specificity ([@B6]). Transcriptome analysis of human pancreatic endocrine and exocrine cells detected glucagon receptor (*Gcgr)* expression in ductal cells, but *Glp1r* expression was not reported ([@B21]). Despite immunohistochemical depiction of robust GLP-1R immunopositivity in human pancreatic cancer cells ([@B22]), using transcriptome analysis of publicly available databases (oncomine.com, version 4.4.3, and Genome Expression Omnibus, <http://www.ncbi.nlm.nih.gov/geo/>) we have been unable to find evidence that *Glp1r* mRNA transcripts are overexpressed in these tumors. Similarly, using in situ ligand binding and autoradiography, Körner et al. ([@B23]) were unable to detect GLP-1 binding sites in pancreatic adenocarcinomas. New studies using individual endocrine or acinar cells purified by fluorescence-activated cell sorter analysis or isolation of single pancreatic cells using laser-capture microdissection followed by the use of validated antisera and/or PCR analysis using primers that span the full-length *Glp1r* open reading frame should refine our understanding of the direct cellular targets of GLP-1 action in the pancreas.

Incretin-mediated control of islet hormone secretion. {#s2}
-----------------------------------------------------

The increasing realization that β-cells exhibit considerable functional heterogeneity begs the question of whether there is a gradient of incretin receptor expression and action in different β-cells and whether these putative gradients vary among islets of different size and location across species. Although the insulin-stimulating properties of GLP-1R agonists are preserved in experimental models of diabetes and human subjects with type 2 diabetes (T2D), the actions of GIP on the diabetic β-cell likely are attenuated because of downregulation of *Gipr* expression and/or attenuation of signaling pathways coupling GIP receptor activation to insulin secretion ([@B2]). The loss of GIP action in the diabetic pancreas is reversible in animal and human studies. Reduction of glycemia with phlorizin restores islet GIP receptor expression and insulin secretion in response to GIP in diabetic rats ([@B24],[@B25]), whereas treating human subjects with T2D with insulin for 4 weeks to reduce levels of glycated hemoglobin to ∼7% significantly improves the insulin secretory response to exogenous GIP ([@B26]).

GLP-1 and GIP exert different actions on islet α-cells. GLP-1R agonists (and DPP-4 inhibitors) inhibit glucagon secretion in normoglycemic and diabetic animals and humans ([@B27]), most likely via GLP-1R--dependent stimulation of islet somatostatin secretion. In turn, somatostatin inhibits glucagon secretion through expression of somatostatin receptor 2 on α-cells ([@B28]). Conversely, GIP stimulates glucagon secretion in humans under conditions of hyperglycemia ([@B29],[@B30]), but whether these actions reflect direct activation of α-cell GIP receptors ([@B29]) remains unclear. Intriguingly, rodent and human α-cells express immunoreactive and bioactive GIP, hence an intraislet paracrine or autocrine GIP axis, with locally produced GIP acting through α-cell GIP receptors, cannot be excluded ([@B31]).

PANCREATIC INCRETIN RECEPTOR SIGNALING: CELL PROLIFERATION AND APOPTOSIS {#s3}
========================================================================

Expansion of β-cell mass. {#s4}
-------------------------

Multiple preclinical studies demonstrate proliferative and antiapoptotic actions of GLP-1, leading to the expansion of β-cell mass ([@B32]). Early experiments promoted the concept that GLP-1R agonists stimulated neogenesis of β-cells via activation of a ductal cell GLP-1R ([@B2],[@B32]). However, the contribution of β-cell neogenesis from ductal precursors to a generation of new β-cells in adult mice has been elegantly disputed ([@B33]). Antiapoptotic actions of GLP-1R agonists have been demonstrated in rodent and human islets ([@B2],[@B32]) and in preclinical studies of transplanted human islet cells. Results of clinical studies assessing whether GLP-1R agonists preserve β-cell function in subjects with type 1 diabetes (T1D) or T2D are more disappointing. There is little evidence that in subjects with T2D prolonged therapy with GLP-1R agonists modifies the progressive decline in β-cell function, an indirect surrogate of β-cell mass, independent of changes in weight loss ([@B34]). Similarly, treatment with exenatide for 6--9 months in subjects with long-standing T1D who are C-peptide-positive, with or without immunosuppression (daclizumab), did not enhance β-cell function or suppress meal-stimulated glucagon levels ([@B35]). The available evidence from randomized controlled trials does not support the contention that exenatide or liraglutide produce a sustained or progressive improvement in β-cell function in subjects with T1D following islet transplantation.

Why have we not seen clinical evidence of expansion of functional β-cell mass in diabetic subjects treated with GLP-1R agonists or DPP-4 inhibitors? The majority of positive preclinical experiments were carried out in younger animals ([@B2]), whereas older rodent β-cells exhibit a substantially diminished or absent proliferative response to multiple regenerative stimuli, including GLP-1R agonists ([@B36],[@B37]). The diminution in the replicative capacity of β-cells in response to GLP-1R agonists has been attributed to loss of proteins that regulate the cell cycle, such as Skp2 (that controls p27), and sustained expression of p16Ink4a in older rodent and human β-cells ([@B38]). Human β-cells seem to be much less responsive to proliferative agents such as GLP-1 compared to rodent β-cells ([@B39]), and β-cell replication is substantially diminished in older human subjects ([@B40]). Hence more work is required to understand whether an older diabetic human β-cell retains a meaningful capacity to proliferate, resist cell death, or retain a functional differentiated state in response to GLP-1R agonists.

Control of α-cell mass. {#s5}
-----------------------

Multiple studies demonstrate that GLP-1R agonists and DPP-4 inhibitors inhibit glucagon secretion ([@B2],[@B27]). Surprisingly, hyperplasia of glucagon-producing α-cells was described in pancreata from diabetic human subjects who received sitagliptin (*n* = 7) or exenatide (*n* = 1) for at least 1 year, leading to speculation that exposure to DPP-4 inhibitors and/or GLP-1R agonists promotes α-cell hyperplasia via a reduction in glucagon secretion ([@B5]). Ki67+ proliferating α-cells were not detected in these pancreata; hence putative mechanisms linking incretin action to expansion of α-cell mass remain unknown. Remarkably, the diabetic controls and subjects treated with incretin were substantially mismatched with regard to age, duration of diabetes, sex, age at onset of diabetes, medication profile, and history of ketoacidosis, precluding any meaningful interpretation of the data. Furthermore, these observations are contradicted by extensive preclinical studies in rodents and nonhuman primates that failed to detect α-cell hyperplasia despite systemic multiples of exposures to GLP-1R agonists or DPP-4 inhibitors much greater than those achieved in human subjects ([@B41]--[@B44]). Because the majority (7/8) of human pancreata studied were from subjects taking sitagliptin ([@B5]), we reviewed preclinical studies of DPP-4 inhibitors that reported changes in α-cell numbers ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0822/-/DC1)). One of 20 studies described an increase in α-cells, 6 studies reported no change in α-cells, and 13 articles described a reduction in α-cell number, decreased α-cell proliferation, or both. Hence a substantial body of independent scientific experimentation ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0822/-/DC1)), taken together with extensive preclinical data spanning thousands of mice, rats, and monkeys ([@B41]--[@B44]), consistently reports α-cell findings diametrically opposed to those reported in a small human autopsy pancreas study ([@B5]).

Scientists reporting α-cell hyperplasia in pancreata from subjects treated with sitagliptin or exenatide envisioned a pathway linking GLP-1--mediated reduction of glucagon secretion to an expansion of α-cell mass independent of changes in α-cell proliferation ([@B5]). Complete genetic attenuation of *Gcgr* expression in all tissues or extinction of glucagon receptor signaling in the liver leads to compensatory expansion of α-cell mass in an attempt to restore glucagon action, which is achieved via mechanisms linked to increased α-cell proliferation ([@B45],[@B46]) ([Fig. 2](#F2){ref-type="fig"}). However, the robust expansion of α-cell mass secondary to elimination of Gcgr signaling is independent of GLP-1R signaling ([@B47],[@B48]). Furthermore, heterozygous *Gcgr*^+/−^ mice do not exhibit α-cell hyperplasia and less than complete blockade of the Gcgr using a Gcgr antagonist administered to mice fed a high-fat diet for 82 days did not result in α-cell hyperplasia ([@B49]). Complete elimination of glucagon production also leads to α-cell hyperplasia ([@B50]); however, DPP-4 inhibitors or GLP-1R agonists generally produce a 20--50% reduction in plasma glucagon levels ([@B27],[@B51]), a scenario that has never been shown to trigger α-cell hyperplasia. Hence a large amount of independent experimentation refutes the existence of a speculative pathway ([@B5]) linking partial reduction of glucagon secretion to expansion of α-cell mass and neuroendocrine tumor formation independent of changes in α-cell proliferation.

![GLP-1 and DPP-4 inhibitor action in the endocrine pancreas. GLP-1R agonists and DPP-4 inhibitors enhance insulin and reduce glucagon secretion. In preclinical studies, these agents expand β-cell mass and reduce α-cell mass. Genetic mutations that disrupt glucagon receptor signaling or eliminate production of bioactive glucagon result in islet α-cell hyperplasia.](3316fig2){#F2}

Acinar and ductal cells. {#s6}
------------------------

Notwithstanding the uncertainty about whether rodent or human acinar and ductal cells express a functional GLP-1R, older rodent pancreatic ductal cells retain the capacity to proliferate following GLP-1R activation. Indeed, a threefold increase in ductal proliferation was observed after a 7-day course of exendin-4 in three 7-month-old mice ([@B38]). Nevertheless, the hypothesis that sustained GLP-1R signaling and/or inhibition of Gcgr signaling (which also increases levels of GLP-1) will promote exocrine cell proliferation, leading to the expansion of exocrine mass ([@B5]), has not been consistently reproduced in nonsensitized preclinical models. Treatment with exendin-4 for 12 weeks in transgenic mice expressing an activated *K-ras* oncogene increased the expression of low-grade pancreatic intraepithelial neoplasia and enhanced ductal cell proliferation, but acinar cell proliferation was not reported ([@B10]). The assertion that *Gcgr*^−/−^ mice or humans with a *Gcgr* null mutation exhibit enhanced exocrine proliferation ([@B5]) is not supported by the published data ([@B52],[@B53]) cited by the same authors. Although *Gcgr*^−/−^ mice exhibit pancreatic enlargement, increased acinar or ductal cell proliferation has not been detected by multiple independent groups that have studied these animals ([@B45],[@B46],[@B48],[@B52]).

Histological analyses of the pancreas have been carried out after extensive chronic treatment (up to 2 years) with high doses of GLP-1R agonists in thousands of mice and rats and dozens of monkeys. None of the studies involving multiple doses of structurally distinct GLP-1R agonists has reported expansion of the ductal or exocrine compartments in rodents or nonhuman primates ([@B41],[@B42]). Similarly, the DPP-4 inhibitors vildagliptin or sitagliptin, which were administered to hundreds of mice and rats continuously for 2 years ([@B43],[@B44]) at doses producing high multiples of systemic drug exposure, did not result in acinar, ductal, or endocrine cell neoplasia. Although data from toxicology studies of diabetic animals is limited, a 3-month treatment regimen of exenatide twice daily at doses of 6, 40, and 250  µg/kg/day produced no changes in pancreatic exocrine structure or ductal proliferation ([@B54]). Similarly, no proliferative effects of exenatide or liraglutide were detected in the exocrine pancreas of diabetic Zucker diabetic fatty rats after 13 weeks of drug administration ([@B55]). Sitagliptin was administered for 3 months in monkeys, 12 months in dogs, and 24 months in mice and rats at doses producing levels of exposure considerably higher than those achieved clinically; no evidence of pancreatic abnormalities were detected on gross or histological analysis of the pancreas. However, precise details on the actual analyses carried out in these toxicology studies have not yet been published ([@B44]). Each pharmaceutical sponsor of a DPP-4 inhibitor or GLP-1R agonist is required to carry out 2-year carcinogenicity studies in 2 species; there have now been thousands of animals exposed to DPP-4 inhibitors and GLP-1R agonists in addition to the studies reported above. However, reports of ductal or acinar proliferation or pancreatic adenocarcinoma in preclinical studies, either in the form of toxicology reports submitted as part of new drug applications to regulatory authorities or as published manuscripts, have not yet been forthcoming.

Nevertheless, GLP-1R agonists increase the weight of the pancreas in some preclinical studies, most notably in young rodents ([@B10],[@B56]), through mechanisms that are not completely understood. Selective restoration of the expression of human GLP-1R under the control of the Pdx1 promoter in β-cells and ducts normalized glucose homeostasis in *Glp1r*^−/−^ mice but was not sufficient to mediate an increase in pancreatic weight in response to exogenous exendin-4 ([@B57]). Therefore, although insulin secretion is not sufficient for the increase in pancreatic mass observed secondary to GLP-1R activation, further studies are required to elucidate the precise cell types and mechanisms linking GLP-1R activation to changes in pancreatic weight.

GLP-1R signaling, DPP-4 inhibition, and pancreatic inflammation. {#s7}
----------------------------------------------------------------

The glucose reduction achieved with DPP-4 inhibitors requires intact GLP-1R and GIP receptor signaling ([@B58],[@B59]); however, non-glucoregulatory actions may be mediated by other substrates, including stromal-derived cell factor-1α ([@B3],[@B60]). There are few data linking nonenzymatic signaling of DPP-4 to specific actions in the endocrine or exocrine pancreas. The widespread expression of GLP-1Rs on multiple immune cell populations ([@B61]), together with the expression and activity of DPP-4(CD26) in the immune system, provides a logical basis for exploring whether GLP-1R agonists and/or DPP-4 inhibitors modulate immune function. The majority of actions ascribed to DPP-4 in immune cells are attributable to nonenzymatic actions of the enzyme; hence DPP-4 signaling in immune cells proceeds independent of its catalytic enzyme activity ([@B62]). Accordingly, partial inhibition of the catalytic activity of DPP-4 using highly selective DPP-4 inhibitors would not be predicted to perturb immune function ([@B60]). Indeed, T-cell--dependent immune responses are preserved in *Dpp4*^−/−^ mice and in mice treated with a highly selective DPP-4 inhibitor ([@B63]). Preclinical studies linking incretin action to enhanced pancreatic inflammation include the observation that one of eight human islet amyloid polypeptide (hIAPP) transgenic rats treated with sitagliptin for 12 weeks developed focal pancreatic inflammation ([@B64]).

In an attempt to reproduce abnormalities reported in the exocrine pancreas of hIAPP transgenic rats treated with sitagliptin for 12 weeks ([@B64]), Aston-Mourney et al. ([@B65]) fed hIAPP transgenic mice a high-fat diet and treated them with sitagliptin or metformin alone or in combination for 12 months. In contrast to findings observed in hIAPP transgenic rats ([@B64]), islet amyloid deposition, ductal cell proliferation, and pancreatic mass were not increased by sitagliptin in hIAPP transgenic mice; however, β-cell mass was increased, consistent with the known actions of sitagliptin in mice ([@B2]). Furthermore, sitagliptin treatment was not associated with pancreatic inflammation, necrosis, metaplasia, neoplasia, or periductal fibrosis; pancreatic mass was increased in mice treated with metformin but not in mice treated with sitagliptin ([@B65]).

Two reports describe nondiabetic rats treated with exenatide that developed pancreatic damage and inflammation ([@B66],[@B67]). Notably, in both experiments, rats treated with exenatide experienced profound weight loss (25--30%); however, no pair-fed controls were included in these analyses, and mechanisms linking GLP-1R activation to increased pancreatic inflammation were not identified ([@B66],[@B67]). Rapid, profound weight loss is frequently associated with a catabolic state, whereas more modest and gradual weight loss, particularly in the setting of preexisting obesity, is generally associated with reduced tissue and systemic markers of inflammation.

Increased pancreatic inflammation has not been detected in multiple preclinical studies examining chronic effects (up to 2 years) of administration of high doses of GLP-1R agonists or DPP-4 inhibitors in nondiabetic rodents or nonhuman primates ([@B41]--[@B44]). For example, treatment of diabetic rats with supratherapeutic doses of exenatide or liraglutide for 13 weeks was not associated with histological or biochemical evidence of pancreatic inflammation ([@B54],[@B55]). Moreover, administration of GLP-1R agonists before or after the induction of experimental pancreatitis did not enhance pancreatic inflammation in normal or diabetic rats and mice ([@B68],[@B69]); GLP-1R agonists unexpectedly induced an anti-inflammatory gene expression profile in the pancreas of insulin-resistant mice fed a high-fat diet ([@B68]).

Incretin-based therapies and inflammatory markers in humans. {#s8}
------------------------------------------------------------

Small increases in plasma levels of amylase and lipase have been reported in diabetic subjects treated with the DPP-4 inhibitors alogliptin and sitagliptin ([@B70]), and a separate observational study of diabetic subjects treated with sitagliptin, saxagliptin, or exenatide reported that 35.6% of subjects exhibited increases in plasma levels of amylase and/or lipase, with levels of lipase increasing to a relatively greater extent ([@B71]). Notably, elevated levels of amylase and lipase also were observed, albeit less frequently, in diabetic control subjects who did not receive a DPP-4 inhibitor or GLP-1R agonist. Further study is required to determine whether the increase in amylase and lipase reflects subclinical pancreatic inflammation or dysregulated synthesis, secretion, or clearance of these enzymes. Administration of GLP-1R agonists or DPP-4 inhibitors is associated with suppression of inflammation ([@B72]); however, many of these experiments do not control for concomitant reduction in glucose or body weight, which may also indirectly dampen inflammation. Exenatide administered twice daily for 12 weeks in subjects with T2D reduced circulating markers of inflammation in circulating mononuclear cells, independent of changes in body weight ([@B73]). A single, acute, 5-μg injection of exenatide significantly and rapidly reduced levels of reactive oxygen species, nuclear factor-κB binding activity, and expression of tumor necrosis factor-α, interleukin-1β, Jun NH~2~-terminal kinase-1, Toll-like receptor-4, and suppressor of cytokine signaling-3 mRNA transcripts in RNA isolated from circulating mononuclear cells ([@B73]). Similarly, administration of sitagliptin 100 mg once daily for 12 weeks to 12 subjects with T2D reduced expression of proinflammatory markers in circulating mononuclear cells, whereas acute administration of 100 mg sitagliptin to fasting diabetic subjects significantly reduced mononuclear cell expression of Toll-like receptor-2, IκB kinase β, chemokine receptor type 2, cluster of differentiation-26 mRNA transcripts and decreased nuclear factor-κB binding activity ([@B74]). Hence the available data indicate that GLP-1R agonists and DPP-4 inhibitors independently exert anti-inflammatory actions in tissues such as the exocrine and endocrine pancreas, as well as in circulating blood cells from diabetic subjects, although the mechanisms mediating these actions remain poorly understood.

SUMMARY AND PERSPECTIVE {#s9}
=======================

The potential promise of incretin-based therapies has been partially realized in that we can now implement antidiabetic regimens associated with lower rates of hypoglycemia and weight gain. Although the first actions of GLP-1 on pancreatic islet cells were described more than 25 years ago, we still have much to learn about how GLP-1R signaling regulates β-cell function. For example, the molecular mechanisms underlying glucose-sensitive GLP-1R signaling have remained elusive. The precise cellular localization of the GLP-1R in islet and exocrine cells requires more careful study, not only in animals, but also in pancreata from human subjects over a broad range of ages and with and without preexisting diabetes or diseases of the pancreas.

Possible perils of incretin therapies include the development of complications, including pancreatitis and cancer. Although some studies combine groups of experimental subjects exposed to DPP-4 inhibitors and GLP-1R agonists for pooled analyses of adverse events ([@B5],[@B75]), these two distinct drug classes exhibit mechanisms of action with multiple fundamental differences ([@B2],[@B60]). Therefore it is not scientifically justifiable to pool subjects exposed to DPP-4 inhibitors and GLP-1R agonists. The hypothesis that activation of GLP-1R signaling might promote increased cell proliferation and increase the incidence or detection of specific neoplasms is reasonable. Indeed, rats and, to a lesser extent, mice exhibit C-cell hyperplasia and medullary thyroid cancer after prolonged, sustained exposure to GLP-1R agonists ([@B76]). Nevertheless, monkeys and humans exhibit major differences in GLP-1R expression in their thyroid C-cells, and in the vast majority of subjects calcitonin levels do not rise into the abnormal range following prolonged exposure to GLP-1R agonists ([@B77]). Studies assessing the pancreata of thousands and mice and rats have not shown dysplasia or tumor formation following treatment with GLP-1R agonists or DPP-4 inhibitors for periods up to 2 years. Furthermore, GLP-1 levels remain substantially elevated for years following many forms of bariatric surgery, yet rates of pancreatitis, medullary thyroid cancer, glucagonomas, and cancer of the pancreas are not increased in this patient population, despite more than 10 years of follow-up ([@B78]). Hence the hypothesis that GLP-1R agonists or DPP-4 inhibitors will promote tumor formation ([@B4]) is not supported by the available preclinical or clinical data.

Experimental evidence raising the possibility that incretin-based therapy may be associated with a predisposition to develop pancreatitis or pancreatic cancer generates important hypotheses that require testing in mechanistic preclinical studies and independent validation in large randomized, controlled clinical trials. Pathological pitfalls of incretin-based science include the use of nonspecific antisera and mismatched cases and controls and the generation of nonvalidated hypotheses and irreproducible data. As millions of patients with diabetes are being treated with incretin-based therapies, our collective responsibility to use higher-quality science has never been greater. Underpowered studies using poorly validated reagents or analysis of mismatched cases and controls ([@B5]) have a much greater certainty of not being reproducible and do not advance our understanding of incretin action in the pancreas. Emerging pharmacovigilance studies, such as the Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD) study should shed additional clarity on the risk-to-benefit ratio of medications used to treat diabetes.

A great deal has been written about incretin action in the pancreas, including statements that are not substantiated or are contradicted by available data. For example, the claim that "production of exendin-4 causes rapid proliferation of intestinal tissue and a 50% increase in the size of the pancreas" ([@B79]) in *Heloderma suspectum* is simply incorrect and is clearly refuted by the actual experimental data cited ([@B80]). The ongoing debate surrounding the mechanisms of action and potential safety of incretin-based therapies reminds one of a quotation variably attributed to Daniel Patrick Moynihan, James Schlesinger, or Bernard Baruch: "Everyone is entitled to their own opinions, but they are not entitled to their own facts." The beauty of science is that it is self-correcting, and provocative experiments and observations that are not highly reproducible are ultimately discarded. Over the next several years we will learn much more about the potential risks and benefits of incretin-based therapies from large, randomized, ongoing cardiovascular outcome studies, with rigorous independent adjudication of adverse events. Thoughtful scientists await the results of these and ongoing pharmacovigilance studies with great interest. The results of these trials will be extremely useful for increasing our understanding of incretin action in not only the cardiovascular system but also the diabetic pancreas.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-0822/-/DC1>.
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